IMNN
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- IMUNON highlights the case for its Phase 3 IMNN-001 study, citing a 14.7-month overall survival signal, improved IL-12 safety and enrollment ahead of scheduleSep 24, 2026
- IMUNON announced plans to host its 2026 R&D Day highlighting the Phase 3 OVATION 3 trial and the clinical potential of IMNN-001Aug 26, 2026
- IMUNON reported strong enrollment momentum in the Phase 3 OVATION 3 trial of IMNN-001 for advanced ovarian cancerJul 31, 2026
- IMUNON reports positive Phase 2 MRD data for IMNN-001, demonstrating improved IL-12 safety in frontline ovarian cancerJul 22, 2026
- IMUNON reported that the Data Monitoring Committee recommended continuing the Phase 3 OVATION 3 study without changesJun 23, 2026